CR20160123A - Inhibidores de polimerasa hcv - Google Patents

Inhibidores de polimerasa hcv

Info

Publication number
CR20160123A
CR20160123A CR20160123A CR20160123A CR20160123A CR 20160123 A CR20160123 A CR 20160123A CR 20160123 A CR20160123 A CR 20160123A CR 20160123 A CR20160123 A CR 20160123A CR 20160123 A CR20160123 A CR 20160123A
Authority
CR
Costa Rica
Prior art keywords
hcv polymerase
polymerase inhibitors
prophylaxis
hepatitis
variables
Prior art date
Application number
CR20160123A
Other languages
English (en)
Spanish (es)
Inventor
Genadiy Kalayanov
Staffan Torssell
Horst Wähling
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52628746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20160123(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of CR20160123A publication Critical patent/CR20160123A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/073Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CR20160123A 2013-09-04 2016-03-10 Inhibidores de polimerasa hcv CR20160123A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE1351026 2013-09-04
SE1351169 2013-10-03
SE1450152 2014-02-12
PCT/SE2014/051005 WO2015034420A1 (en) 2013-09-04 2014-09-02 Hcv polymerase inhibitors

Publications (1)

Publication Number Publication Date
CR20160123A true CR20160123A (es) 2016-07-20

Family

ID=52628746

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160123A CR20160123A (es) 2013-09-04 2016-03-10 Inhibidores de polimerasa hcv

Country Status (28)

Country Link
US (5) US9481703B2 (index.php)
EP (2) EP3041855B1 (index.php)
JP (2) JP6456958B2 (index.php)
KR (1) KR20160078337A (index.php)
CN (3) CN108676047B (index.php)
AU (2) AU2014315715B2 (index.php)
BR (1) BR112016004919A2 (index.php)
CA (1) CA2921899A1 (index.php)
CL (2) CL2016000493A1 (index.php)
CR (1) CR20160123A (index.php)
CY (1) CY1119587T1 (index.php)
DK (1) DK3041855T3 (index.php)
EA (1) EA028974B1 (index.php)
HR (1) HRP20171435T1 (index.php)
HU (1) HUE036365T2 (index.php)
IL (2) IL244389B (index.php)
ME (1) ME02875B (index.php)
MX (1) MX2016002849A (index.php)
MY (1) MY177804A (index.php)
PH (2) PH12016500402A1 (index.php)
PL (1) PL3041855T3 (index.php)
PT (1) PT3041855T (index.php)
RS (1) RS56383B1 (index.php)
SA (1) SA516370684B1 (index.php)
SG (2) SG11201601474UA (index.php)
SI (1) SI3041855T1 (index.php)
UA (1) UA117375C2 (index.php)
WO (1) WO2015034420A1 (index.php)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2773773C (en) 2009-09-21 2019-04-23 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
CN104151360B (zh) * 2013-05-14 2019-02-22 北京美倍他药物研究有限公司 磷酸/膦酸衍生物及其医药用途
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
WO2015081297A1 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US10030044B2 (en) 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
US20170037078A1 (en) * 2014-04-24 2017-02-09 Cocrystal Pharma, Inc. 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
CN105315319B (zh) * 2014-07-30 2020-11-20 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
CR20220034A (es) 2014-12-30 2022-02-11 Dow AgroSciences LLC Compuestos de picolinamida con actividad fungicida (divisional 2017-0308)
EP3240408B1 (en) 2014-12-30 2020-04-08 Dow Agrosciences LLC Picolinamides with fungicidal activity
KR20170100550A (ko) * 2014-12-30 2017-09-04 다우 아그로사이언시즈 엘엘씨 살진균 활성을 갖는 피콜린아미드 화합물
JP6715250B2 (ja) 2014-12-30 2020-07-01 ダウ アグロサイエンシィズ エルエルシー 殺真菌活性を有するピコリンアミド化合物
WO2016134057A1 (en) * 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
AU2016226647A1 (en) * 2015-03-02 2017-09-21 Medivir Ab Nucleotide phosphoramidate formulation
HK1243712A1 (zh) * 2015-03-02 2018-07-20 美迪维尔公司 作为用於治疗丙型肝炎的hcv抑制剂的核苷酸衍生物
WO2016160646A1 (en) * 2015-04-02 2016-10-06 Merck Sharp & Dohme Corp. Process for making phosphoramidate protected nucleoside compounds
US10011629B2 (en) * 2015-05-01 2018-07-03 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
WO2017040889A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040895A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040892A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040898A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040896A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
EP3344642A1 (en) * 2015-09-02 2018-07-11 AbbVie Inc. Anti-viral tetrahydrofurane derivatives
MX394858B (es) 2015-09-16 2025-03-24 Gilead Sciences Inc Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae
CN105367505A (zh) * 2015-12-01 2016-03-02 苏利制药科技江阴有限公司 一种新型合成3,6-二甲基-2,5-哌嗪二酮的方法
CA3011538A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamantane derivatives for the treatment of filovirus infection
WO2018033593A1 (en) * 2016-08-19 2018-02-22 Sandoz Ag Sofosbuvir derivatives for the treatment of hepatitis c
EP3595672B1 (en) 2017-03-14 2023-09-06 Gilead Sciences, Inc. Compounds for use in methods of treating feline coronavirus infections
EP4219513A1 (en) 2017-05-01 2023-08-02 Gilead Sciences, Inc. Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
TW201842851A (zh) 2017-05-02 2018-12-16 美商陶氏農業科學公司 用於穀類中的真菌防治之協同性混合物
TWI774761B (zh) 2017-05-02 2022-08-21 美商科迪華農業科技有限責任公司 用於穀物中的真菌防治之協同性混合物
CA3062074A1 (en) 2017-05-02 2018-11-08 Dow Agrosciences Llc Use of an acyclic picolinamide compound as a fungicide for fungal diseases on turfgrasses
TW201919648A (zh) 2017-07-11 2019-06-01 美商基利科學股份有限公司 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
BR102019004480B1 (pt) 2018-03-08 2023-03-28 Dow Agrosciences Llc Picolinamidas como fungicidas
EP3762394A4 (en) 2018-03-09 2021-12-08 Medivir Aktiebolag CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENE CYCLOPROPANE CLEOTIDES
WO2020081382A1 (en) 2018-10-15 2020-04-23 Dow Agrosciences Llc Methods for sythesis of oxypicolinamides
CN109762040A (zh) * 2019-01-14 2019-05-17 歌礼生物制药(杭州)有限公司 一种核苷类ns5b聚合酶抑制剂的制备方法
CN114554848A (zh) 2019-10-18 2022-05-27 科迪华农业科技有限责任公司 用于合成吡啶酰胺的方法
EP4096678A1 (en) 2020-01-27 2022-12-07 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN111269263A (zh) * 2020-03-09 2020-06-12 上海龙翔生物医药开发有限公司 一种瑞德西韦侧链中间体及其制备方法
CN115298181B (zh) 2020-03-12 2024-08-16 吉利德科学公司 制备1’-氰基核苷的方法
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN111848679A (zh) * 2020-04-17 2020-10-30 山东科巢生物制药有限公司 一种利用微通道反应技术合成瑞德西韦的方法
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof
CA3190702A1 (en) 2020-08-27 2022-03-03 Elaine Bunyan Compounds and methods for treatment of viral infections
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CR20240363A (es) 2022-03-02 2024-10-25 Gilead Sciences Inc Compuestos y métodos para el tratamiento de infecciones virales.
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN116199679A (zh) * 2022-12-23 2023-06-02 吉斯凯(苏州)制药有限公司 一种拉米夫定的工业化制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2135890C (en) 1992-12-29 1996-08-27 Dale J. Kempf Retroviral protease inhibitor (2s,3s,5s)-5-(n-(n-((n-methyl-n-((2-isopropyl-4- thiazolyl)methyl)amino)carbonyl)valinyl)amino)- 2-(n-((5-thiazolyl)methoxycarbonyl)amino)-1, 6-diphenyl-3-hydroxyhexane
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
BR0114837A (pt) * 2000-10-18 2006-05-09 Pharmasset Ltd nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
WO2008022469A1 (en) * 2006-08-23 2008-02-28 Mcgill University 2'-DEOXY-2'-FLUORO-β-D-ARABINONUCLEOSIDE 5'-TRIPHOSPHATES AND THEIR USE IN ENZYMATIC NUCLEIC ACID SYNTHESIS
JP2010505902A (ja) * 2006-10-10 2010-02-25 メディヴィル・アクチエボラーグ Hcvヌクレオシド阻害剤
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2710832A1 (en) 2007-12-27 2009-07-09 Epiphany Biosciences, Inc. Antiviral compounds
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
JP2012521359A (ja) * 2009-03-20 2012-09-13 アリオス バイオファーマ インク. 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
CN101591371B (zh) * 2009-06-30 2012-05-30 连云港金康医药科技有限公司 一种通过卤交换氟化制备吉西他滨或其类似物的方法
EP3290428B1 (en) 2010-03-31 2021-10-13 Gilead Pharmasset LLC Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
US8402690B2 (en) 2010-09-09 2013-03-26 Sterling International Inc. Bedbug trap
US20120070411A1 (en) * 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
KR20130110170A (ko) * 2010-09-22 2013-10-08 앨리오스 바이오파마 인크. 치환된 뉴클레오타이드 유사체
CA2832459A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
WO2013096679A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
US10030044B2 (en) * 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
WO2015081297A1 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US20170037078A1 (en) 2014-04-24 2017-02-09 Cocrystal Pharma, Inc. 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer

Also Published As

Publication number Publication date
US20150175648A1 (en) 2015-06-25
SG10201700647PA (en) 2017-02-27
IL244389B (en) 2018-10-31
UA117375C2 (uk) 2018-07-25
CY1119587T1 (el) 2018-03-07
EP3252066A1 (en) 2017-12-06
PT3041855T (pt) 2017-11-08
JP2019065011A (ja) 2019-04-25
CN108558973A (zh) 2018-09-21
KR20160078337A (ko) 2016-07-04
CN108676047A (zh) 2018-10-19
SG11201601474UA (en) 2016-03-30
CN105705510B (zh) 2018-11-30
ME02875B (me) 2018-04-20
US20180105549A1 (en) 2018-04-19
IL261702A (en) 2018-10-31
HK1255872A1 (zh) 2019-08-30
EP3041855B1 (en) 2017-07-26
SI3041855T1 (sl) 2017-11-30
PL3041855T3 (pl) 2018-03-30
PH12016500402B1 (en) 2016-05-16
HRP20171435T1 (hr) 2017-11-03
JP2016529324A (ja) 2016-09-23
US10106571B2 (en) 2018-10-23
BR112016004919A2 (pt) 2017-09-05
PH12016500402A1 (en) 2016-05-16
US20160340380A1 (en) 2016-11-24
US20170107244A1 (en) 2017-04-20
US9540411B2 (en) 2017-01-10
CN105705510A (zh) 2016-06-22
EA201690452A1 (ru) 2016-08-31
DK3041855T3 (en) 2017-10-23
CA2921899A1 (en) 2015-03-12
PH12018500931A1 (en) 2019-02-04
JP6456958B2 (ja) 2019-01-23
AU2017203954A1 (en) 2017-07-06
SA516370684B1 (ar) 2017-05-10
EA028974B1 (ru) 2018-01-31
HK1221228A1 (zh) 2017-05-26
IL244389A0 (en) 2016-04-21
CL2016000493A1 (es) 2016-12-23
WO2015034420A1 (en) 2015-03-12
EP3252066B1 (en) 2019-05-22
CN108676047B (zh) 2021-04-02
CL2019000271A1 (es) 2019-06-07
US9481703B2 (en) 2016-11-01
AU2014315715B2 (en) 2017-04-06
IL261702B (en) 2019-05-30
EP3041855A1 (en) 2016-07-13
US20190085010A1 (en) 2019-03-21
AU2017203954B2 (en) 2019-05-09
US9828408B2 (en) 2017-11-28
RS56383B1 (sr) 2017-12-29
HUE036365T2 (hu) 2018-07-30
MY177804A (en) 2020-09-23
MX2016002849A (es) 2016-10-26
AU2014315715A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
CL2019000271A1 (es) Inhibidores de polimerasa hcv. (divisional solicitud 201600493)
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
MX382419B (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
MX2015007925A (es) Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
CR20150611A (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis por el virus de la hepatitis b
SV2017005424A (es) Métodos para tratar infecciones por el virus filoviridae
CR20150085A (es) Nuevas 6-aminoacido-heteroarildihidropirmidindas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
MX2016009337A (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
ECSP15000435A (es) Inhibidores macrocíclicos de virus flaviviridae
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
CO6561783A2 (es) Inhibidores del virus flaviviridae
CL2016003277A1 (es) Métodos para preparar análogos de nucleótido sustituidos
UY35873A (es) ?composiciones y métodos para el control de virus en el ácaro varroa y las abejas?.
MX2014005342A (es) Inhibidores del virus de la hepatitis c.
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
UY34066A (es) Inhibidores del virus de la hepatitis c
DOP2016000278A (es) Nuevos compuestos macrocíclicos
CR20150060A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.